We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Natera Inc (NTRA) USD0.0001

Sell:$61.17 Buy:$61.29 Change: $0.09 (0.15%)
Market closed |  Prices as at close on 19 January 2022 | Switch to live prices |
Sell:$61.17
Buy:$61.29
Change: $0.09 (0.15%)
Market closed |  Prices as at close on 19 January 2022 | Switch to live prices |
Sell:$61.17
Buy:$61.29
Change: $0.09 (0.15%)
Market closed |  Prices as at close on 19 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Natera, Inc. is a diagnostics company. The Company is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free DNA (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.

Contact details

Address:
13011 MCCALLEN PASS
BUILDING A SUITE 100
AUSTIN
78753
United States
Telephone:
+1 (650) 2499090
Website:
www.natera.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NTRA
ISIN:
US6323071042
Market cap:
$6.37 billion
Shares in issue:
94.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Matthew Rabinowitz
    Executive Chairman of the Board, Co-Founder
  • Steven Chapman
    President, Chief Executive Officer, Director
  • Jonathan Sheena
    Co-Founder, Director
  • Michael Brophy
    Chief Financial Officer
  • Robert Schueren
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.